DE69628214T2 - Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori - Google Patents

Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori

Info

Publication number
DE69628214T2
DE69628214T2 DE69628214T DE69628214T DE69628214T2 DE 69628214 T2 DE69628214 T2 DE 69628214T2 DE 69628214 T DE69628214 T DE 69628214T DE 69628214 T DE69628214 T DE 69628214T DE 69628214 T2 DE69628214 T2 DE 69628214T2
Authority
DE
Germany
Prior art keywords
product
definitifs
avancee
intermediaires
amadori
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69628214T
Other languages
English (en)
Other versions
DE69628214D1 (de
Inventor
Billy Hudson
Todd Parvin
Raja Gabriel Khalifah
Aaron Ashley Univ Of Kan Booth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KANSAS UNIVERSITY MEDICAL CT K
University of Kansas Medical Center
Original Assignee
KANSAS UNIVERSITY MEDICAL CT K
University of Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KANSAS UNIVERSITY MEDICAL CT K, University of Kansas Medical Center filed Critical KANSAS UNIVERSITY MEDICAL CT K
Application granted granted Critical
Publication of DE69628214D1 publication Critical patent/DE69628214D1/de
Publication of DE69628214T2 publication Critical patent/DE69628214T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
DE69628214T 1995-09-12 1996-09-11 Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori Expired - Lifetime DE69628214T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US362895P 1995-09-12 1995-09-12

Publications (2)

Publication Number Publication Date
DE69628214D1 DE69628214D1 (de) 2003-06-18
DE69628214T2 true DE69628214T2 (de) 2003-11-27

Family

ID=21706786

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69628214T Expired - Lifetime DE69628214T2 (de) 1995-09-12 1996-09-11 Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori
DE69621645T Expired - Lifetime DE69621645T2 (de) 1995-09-12 1996-09-11 Zwischenverbindungen von fortgeschrittenen glykosylierung-endprodukten und post-amadorische inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69621645T Expired - Lifetime DE69621645T2 (de) 1995-09-12 1996-09-11 Zwischenverbindungen von fortgeschrittenen glykosylierung-endprodukten und post-amadorische inhibitor

Country Status (11)

Country Link
US (4) US5744451A (de)
EP (1) EP0871443B1 (de)
JP (2) JPH11512432A (de)
AT (2) ATE218341T1 (de)
AU (1) AU717485B2 (de)
CA (1) CA2231772C (de)
DE (2) DE69628214T2 (de)
DK (1) DK0871443T3 (de)
ES (2) ES2199913T3 (de)
PT (2) PT871443E (de)
WO (1) WO1997009981A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6740668B1 (en) 1995-08-28 2004-05-25 Kansas University Medical Center Methods for inhibiting diabetic complications
US6730686B1 (en) 1995-09-12 2004-05-04 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 ÎČ converting enzyme inhibitory activity
US6750209B1 (en) 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6436969B1 (en) 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
US20030013746A1 (en) * 1996-09-10 2003-01-16 University Of Kansas Medical Center. Advanced glycation end-product intermediaries and post-amadori inhibition
US7071298B2 (en) 1997-02-05 2006-07-04 Fox Chase Cancer Center Compounds and methods for treating glycogen storage disease and other pathological conditions resulting from formation of age-proteins
AU6518598A (en) * 1997-03-28 1998-10-22 Otsuka Pharmaceutical Co., Ltd. Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b6
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
JP2001513370A (ja) * 1997-08-07 2001-09-04 ă‚°ăƒ—ă‚żïŒŒă‚ąă‚žăƒŁă‚€ æ°Žæș¶æ€§ăƒ“ă‚żăƒŸăƒłćŠăłæ „é€ŠçŽ ă‚’ć«ă‚€é€æžæș¶æ¶Č
US7220717B2 (en) * 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US7704944B2 (en) * 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
DE69925268T2 (de) * 1998-03-16 2006-03-23 Cytovia, Inc., San Diego Dipeptid-Caspase-Inhibitoren und deren Verwendung
KR100928878B1 (ko) 1998-03-19 2009-11-30 ëČ„í…ìŠ€ 파마슈티ìčŒìŠ€ ìžìœ”íŹë ˆìŽí‹°ë“œ ìčŽìŠ€íŒŒì œì˜ 얔제제
US6919326B1 (en) 1998-08-24 2005-07-19 Toshio Miyata Carbonyl-stress improving agent and peritoneal dialysate
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
WO2000021516A2 (en) * 1998-10-14 2000-04-20 Kansas University Medical Center Research Institute, Inc. Methods for inhibiting diabetic complications
CA2347117C (en) * 1998-10-22 2006-01-24 University Of South Carolina Methods for inhibiting diabetic complications
EP1126856A4 (de) * 1998-10-28 2008-05-14 Fox Chase Cancer Ct Verbindungen und ihre therapeutische verwendung in diabetischen komplikationen
US6121300A (en) * 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6342500B1 (en) 1999-03-05 2002-01-29 Kansas University Medical Center Post-Amadori inhibitors of Advanced Glycation reactions
JP2002539183A (ja) 1999-03-16 2002-11-19 ă‚”ă‚€ăƒˆăƒ“ă‚ą ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ çœźæ›ïŒ’âˆ’ă‚ąăƒŸăƒŽăƒ™ăƒłă‚șă‚ąăƒŸăƒ‰ă‚«ă‚čăƒ‘ăƒŒă‚Œă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒăŠă‚ˆăłăăźäœżç”š
WO2000059493A2 (en) * 1999-04-06 2000-10-12 Kansas University Medical Center Improved dialysis solutions and methods
JP2002541237A (ja) 1999-04-09 2002-12-03 ă‚”ă‚€ăƒˆăƒ“ă‚ą ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ă‚«ă‚čăƒ‘ăƒŒă‚Œă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒăŠă‚ˆăłăăźäœżç”š
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6489345B1 (en) * 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
WO2001016093A1 (en) 1999-08-27 2001-03-08 Cytovia, Inc. SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
MXPA02008079A (es) * 2000-02-21 2003-02-27 Applied Research Systems Uso de inhibidores de il-18.
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
WO2002022622A2 (en) 2000-09-13 2002-03-21 Georgetown University Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
ES2367891T3 (es) * 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
WO2002053158A1 (en) * 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ib
DE10134568C2 (de) * 2001-07-16 2003-07-24 Inst Chemo Biosensorik Verfahren zur quantitativen Bestimmung von alpha-Oxoaldehyd
CA2496452A1 (en) * 2002-08-30 2004-03-11 Biostratum, Inc. Inhibitors of post-amadori advanced glycation end products
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
DK1643999T3 (da) * 2003-06-20 2012-01-02 Nephrogenex Inc Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
WO2005018649A1 (ja) * 2003-08-25 2005-03-03 Nagoya Industrial Science Research Institute æœ€ç”‚çł–ćŒ–ç”Łç‰©ç”ŸæˆæŠ‘ćˆ¶ć‰€
JP2007506767A (ja) * 2003-09-25 2007-03-22 ăƒ‡ă‚ŁăƒŒă‚šăƒ ă‚ąă‚€ ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚·ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒźâˆ’ă‚ąă‚·ăƒ«âˆ’ïœŒâˆ’ă‚ąă‚čăƒ‘ăƒ©ă‚źăƒłé…žă‚’ćˆ©ç”šă—ăŸæ–čæł•ăŠă‚ˆăłèŁœé€ ç‰©
AU2005249503B2 (en) 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
US7214799B2 (en) * 2004-02-09 2007-05-08 Biostratum, Inc. Methods for the synthesis of pyridoxamine
NZ588448A (en) 2004-05-15 2012-01-12 Vertex Pharma Treating seizures using interleukin-1beta converting enzyme (ICE) inhibitors
US20060035890A1 (en) * 2004-08-10 2006-02-16 Amit Banerjee Compounds and methods for the treatment of ubiquitin conjugating disorders
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US20080004320A1 (en) * 2004-09-06 2008-01-03 Kowa Co., Ltd. Remedy for Glomerular Disease
DE102005020976A1 (de) * 2005-04-29 2006-11-02 WÖRWAG PHARMA GmbH & Co. KG Prophylaxe und Behandlung von Erkrankungen
WO2006126523A1 (ja) * 2005-05-24 2006-11-30 Tokai University Educational System è…čè†œäżè­·ć‰€
WO2007044309A2 (en) * 2005-10-05 2007-04-19 Vasix Corporation Device and method for inhibiting age complex formation
EP2041114B1 (de) * 2006-07-07 2016-03-02 NephroGenex, Inc. Hemmer fortgeschrittener Glykierungsendprodukte
WO2011099570A1 (ja) 2010-02-10 2011-08-18 ă‚ȘăƒȘザæČč挖æ ȘćŒäŒšç€Ÿ ïŒĄïœ‡ïœ…ç”Łç”ŸæŠ‘ćˆ¶ć‰€
EP2635907A4 (de) 2010-11-05 2014-04-16 Univ Brandeis Ice-gespaltene alpha-synuklein-a-biomarker
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
CN103924249A (zh) * 2013-01-11 2014-07-16 捗äșŹć·„䞚性歊 äž€ç§ćž­ć€«çą±ćĄć•¶ç±»çąłé’ąé…žæŽ—çŒ“èš€ć‰‚ćŠć…¶ćș”甚
EP2986306A4 (de) 2013-04-18 2016-12-07 Armo Biosciences Inc Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
JP6509867B2 (ja) 2013-08-30 2019-05-08 ă‚ąăƒ«ăƒąăƒ»ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚·ăƒŒă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ç–Ÿæ‚ŁćŠăłéšœćźłă‚’æČ»ç™‚ă™ă‚‹ăŸă‚ă«ă‚€ăƒłă‚żăƒŒăƒ­ă‚€ă‚­ăƒłâˆ’ïŒ‘ïŒă‚’äœżç”šă™ă‚‹æ–čæł•
JP6148127B2 (ja) * 2013-09-09 2017-06-14 æ ȘćŒäŒšç€Ÿăƒ‘ăƒŒăƒžă‚±ăƒ ăƒ»ă‚ąă‚žă‚ą ピăƒȘăƒ‰ă‚­ă‚”ăƒŒăƒ«ăƒ»ă‚ąăƒŸăƒŽă‚°ă‚ąăƒ‹ă‚žăƒłèȘ˜ć°Žäœ“ăŸăŸăŻăă‚Œă‚‰ăźćĄ©ă€ćŠăłă€ăăźèŁœé€ æ–čæł•
ES2862139T3 (es) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
CN106573072A (zh) 2014-06-02 2017-04-19 é˜żć°”èŽ«ç”Ÿç‰©ç§‘æŠ€è‚Ąä»œæœ‰é™ć…Źćž é™äœŽèĄ€æž…èƒ†ć›ș醇的æ–čæł•
JP6585060B2 (ja) * 2014-08-29 2019-10-02 æ ȘćŒäŒšç€ŸăƒŹăƒŠă‚”ă‚€ă‚šăƒłă‚č ピăƒȘăƒ‰ă‚­ă‚”ăƒŸăƒłćŒ–ćˆç‰©ćŠăłăƒă‚ąăƒŸăƒłćŒ–ćˆç‰©ă‚’ç”„ăżćˆă‚ă›ăŠăȘă‚‹ćŒ»è–Źç”„æˆç‰©
KR20170068553A (ko) 2014-10-14 2017-06-19 ì•„ë„ŽëȘš ë°”ìŽì˜€ì‚ŹìŽì–žì‹œìŠ€ ìžìœ”íŹë ˆìŽí‹°ë“œ 읞터넘킚-15 ìĄ°ì„±ëŹŒ 및 읎의 용도
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
EP3341012A4 (de) 2015-08-25 2019-03-20 Armo Biosciences, Inc. Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
JP6105111B1 (ja) 2016-03-02 2017-03-29 ć›œç«‹ć€§ć­Šæł•äșșæ±ćŒ—ć€§ć­Š è‡Ș閉ă‚čăƒšă‚Żăƒˆăƒ©ăƒ ç—‡æ”čć–„ç”šç”„æˆç‰©
CN114502546A (zh) 2019-08-01 2022-05-13 æ™źæ‹‰ç‰čæˆˆć…Źćž æ™šæœŸçł–ćŸșćŒ–ç»ˆäș§ç‰©çš„æŠ‘ćˆ¶ć‰‚

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4673M (de) 1965-05-19 1966-12-19
FR7238M (de) 1968-03-27 1969-09-01
CH607773A5 (en) 1974-12-24 1978-10-31 Steigerwald Arzneimittelwerk Process for the preparation of novel pyridoxine derivatives
DE2461742C2 (de) 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxin-5'-phosphorsÀureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2349330A1 (fr) 1976-04-29 1977-11-25 Savini Emile Composition destinee au traitement des hyperlipidemies
US5358960A (en) * 1984-03-19 1994-10-25 The Rockefeller University Method for inhibiting advanced glycosylation of proteins using aminosubstituted imidazoles
US4908446A (en) * 1985-11-14 1990-03-13 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US5140048A (en) * 1984-03-19 1992-08-18 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US5221683A (en) * 1984-03-19 1993-06-22 The Rockefeller University Diaminopyridine compounds and methods of use
US5100919A (en) * 1984-03-19 1992-03-31 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
US5272176A (en) * 1984-03-19 1993-12-21 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US5130324A (en) * 1984-03-19 1992-07-14 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US5262152A (en) * 1984-03-19 1993-11-16 The Rockefeller University Amidrazones and derivatives thereof
US5272165A (en) * 1984-03-19 1993-12-21 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US5175192A (en) * 1984-03-19 1992-12-29 The Rockefeller University Inhibitors of the advanced glycosylation of proteins and methods of use therefor
US5318982A (en) * 1984-03-19 1994-06-07 The Rockefeller University Inhibition of the advanced glycosylation of proteins using substituted-1,2,4-triazoles
US5258381A (en) * 1984-03-19 1993-11-02 The Rockefeller University 2-substituted-2-imidazolines
US5137916A (en) * 1985-11-14 1992-08-11 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US5334617A (en) * 1984-03-19 1994-08-02 The Rockefeller University Amino acids useful as inhibitors of the advanced glycosylation of proteins
US4758583A (en) * 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US5218001A (en) * 1984-03-19 1993-06-08 The Rockefeller University Inhibitors of the advanced glycosylation of proteins and methods of use therefor
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US4983604A (en) * 1987-11-13 1991-01-08 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US5254572A (en) * 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
DE3705549A1 (de) 1987-02-18 1988-09-01 Ulrich Speck Verwendung von pyridoxin-derivaten bei der prophylaxe und therapie von hyperlipidaemien und atherosklerose
US5017696A (en) * 1987-09-17 1991-05-21 The Rockefeller University Advanced glycosylation end products and associated methods
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5242593A (en) * 1988-12-09 1993-09-07 Oberkofler Joerg Method for reducing the build-up of slime and/or film in water circulation systems
WO1991011997A1 (fr) 1990-02-19 1991-08-22 Senju Pharmaceutical Co., Ltd. Inhibiteur de la reaction de maillard
CA2055990A1 (en) 1990-11-22 1992-05-23 David G. Schena Phospholipid-vitamin derivatives and methods for preparation thereof
WO1992022570A1 (en) * 1991-06-14 1992-12-23 Chiron Corporation Inhibitors of picornavirus proteases
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1ÎČ converting enzyme inhibitors
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1ÎČ converting enzyme
US6162828A (en) * 1995-03-31 2000-12-19 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US6228858B1 (en) 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 ÎČ converting enzyme inhibitory activity

Also Published As

Publication number Publication date
EP0871443A1 (de) 1998-10-21
PT1190713E (pt) 2003-09-30
US5985857A (en) 1999-11-16
PT871443E (pt) 2002-10-31
JP3769003B2 (ja) 2006-04-19
CA2231772A1 (en) 1997-03-20
US6472400B1 (en) 2002-10-29
AU717485B2 (en) 2000-03-30
ES2177804T3 (es) 2002-12-16
US5932549A (en) 1999-08-03
ES2199913T3 (es) 2004-03-01
DK0871443T3 (da) 2002-07-01
CA2231772C (en) 2011-05-31
ATE218341T1 (de) 2002-06-15
DE69621645T2 (de) 2002-09-19
ATE240103T1 (de) 2003-05-15
AU7156696A (en) 1997-04-01
JP2005170935A (ja) 2005-06-30
US5744451A (en) 1998-04-28
EP0871443B1 (de) 2002-06-05
WO1997009981A1 (en) 1997-03-20
JPH11512432A (ja) 1999-10-26
DE69621645D1 (de) 2002-07-11
DE69628214D1 (de) 2003-06-18

Similar Documents

Publication Publication Date Title
DE69628214T2 (de) Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori
DE69635458D1 (de) Inhibitoren des interleukin-1-beta konvertierenden enzyms
HUP0100156A2 (hu) FoszfolipĂĄz-A2 inhibitor hatĂĄsĂș indolszĂĄrmazĂ©kok Ă©s alkalmazĂĄsuk gyĂłgyĂĄszati kĂ©szĂ­tmĂ©nyek elƑállĂ­tĂĄsĂĄra
EP0863755A4 (de) Antithrombotische diamine
HUP0103542A2 (hu) Opioid-receptor aktivitĂĄssal rendelkezƑ 4,4-biaril-piperidin szĂĄrmazĂ©kok Ă©s a vegyĂŒleteket tartalmazĂł gyĂłgyĂĄszati kĂ©szĂ­tmĂ©nyek
HUP0101146A2 (hu) FoszfolipĂĄz enzim inhibitor hatĂĄsĂș indolszĂĄrmazĂ©kok, valamint a vegyĂŒleteket tartalmazĂł gyĂłgyĂĄszati kĂ©szĂ­tmĂ©nyek
NZ284846A (en) 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
CA2186511A1 (en) Pyrimidinyl derivatives as interleukin inhibitors
HUP0001539A2 (hu) 2-(1-Imino-etil-amino)-etil-homocisztein, eljĂĄrĂĄs elƑállĂ­tĂĄsĂĄra Ă©s az ezt tartalmazĂł gyĂłgyszerkĂ©szĂ­tmĂ©nyek
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
YU12097A (en) 6-phenilpyridyl-2-amine derivatives
HUP0101791A2 (hu) Gamma-amino-vajsav-szĂĄrmazĂ©kokat tartalmazĂł szilĂĄrd kompozĂ­ciĂłk Ă©s eljĂĄrĂĄs a kompozĂ­ciĂłk elƑállĂ­tĂĄsĂĄra
DK0662948T3 (da) 2-amino-4-phenyl-4-oxosmĂžrsyrederivater med kynureninase- og/eller kynurenin-3-hydroxylaseinhiberende virkning
MY115211A (en) Novel amino acid derivatives, their preparation and use
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituålt ketolidszårmazékok
YU47100A (sh) Novi derivati dihidroksiheksanoinske kiseline
IT1276162B1 (it) Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche
PL346143A1 (en) Tan-1057 derivatives
ES2191099T3 (es) Derivados de hidantoina como productos intermedios para principios activos farmaceuticos.
PL332704A1 (en) Sulphonamide-group substituted derivatives of aspartic acid as inhibitors of an interleukin-1beta transforming enzyme
AU7270798A (en) Antithrombotic agents
ATE253357T1 (de) Bergamottin enthaltende zusammensetzungen zur erhöhung der oralen bioverfĂŒgbarkeit von pharmazeutika
EP1027051A4 (de) Antithrombotische mittel
DE69824410D1 (en) Antithrombosemittel
ES2196566T3 (es) Nuevos compuestos triciclicos de aminooxiamida inhibidores de la farnesil-proteina-transferasa.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition